Ticagrelor versus Clopidogrel in Complex Percutaneous Coronary Intervention in terms of Mortality and Stent Thrombosis
Keywords:
Ticagrelor, Clopidogrel, Percutaneous coronary interventionAbstract
Objective: To compare the effects of ticagrelor and clopidogrel on major adverse cardiovascular events (MACE), 30 day mortality, and stent thrombosis in patients with ST-elevation myocardial infarction (STEMI) undergoing complex percutaneous coronary intervention (PCI).
Methodology: This quasi-experimental study was conducted at the Rawalpindi Institute of Cardiology, Rawalpindi in 3 months from June to August 2025 after ethical approval. After obtaining informed written consent, 376 patients with STEMI treated with complex PCI were included by non-probability convenience sampling technique. The patients were assigned to two groups: Group A received aspirin & clopidogrel, whereas group B received aspirin and ticagrelor. The outcomes assessed were MACE, 30 day mortality, and stent thrombosis. Follow-up was done till 1 month. Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 25.
Results: Bifurcation stenting was present in 80(42.6%) patients in clopidogrel group, while it was seen in 46(24.5%) patients in ticagrelor group. The left main PCI was also more prevalent in the ticagrelor group [81(43.1%)]. The thrombolysis in myocardial infarction (TIMI) 3 flow was restored in 53.7% versus 30.3% of the patients taking ticagrelor and clopidogrel, respectively. Stent thrombosis and MACE were significantly higher in the clopidogrel group (8.5% versus 2.7%) and (19.1% versus 11.2%), respectively. In contrast, no substantial difference was noted regarding 30 day mortality (9% vs. 8%) between the two groups.
Conclusion: Ticagrelor is associated with improved post-PCI TIMI flow, lower incidence of MACE and stent thrombosis in STEMI patients who underwent complex PCI as compared to clopidogrel. However, 30 day mortality is not significantly different in the two groups.
References
1. Kumar M, Shar GS, Kumar R, Shaikh AH, Ishaque H, Khan N, et al. The outcome of primary percutaneous coronary intervention in patients with stent thrombosis. Indian Heart J. 2022; 74(6):464-8. doi:10.1016/j.ihj.2022.11.003.
2. Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual antiplatelet therapy duration in acute coronary syndrome patients: the state of the art and open issues. Cardiovasc Ther. 2020; 2020:6495036. doi:10.1155/2020/6495036.
3. Virk HUH, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, et al. Dual antiplatelet therapy: a concise review for clinicians. Life (Basel). 2023; 13(7):1580. doi:10.3390/life13071580.
4. Karabulut D, Kaya A, Abaci O, Karabulut U, Caglar NT, Arat-Ozkan A. The frequency of aspirin and clopidogrel resistance and related factors in patients undergoing elective percutaneous coronary intervention. E J Cardiovasc Med. 2021; 9(2):94-104. doi:10.32596/ejcm.galenos.2021-02-012.
5. Alexopoulos D, Varlamos C, Benetou DR. Type and duration of dual antiplatelet therapy in complex percutaneous coronary intervention. US Cardiol. 2020; 14:e14. doi:10.15420/usc.2020.13.
6. Wei P, Wang X, Fu Q, Cao B. Progress in the clinical effects and adverse reactions of ticagrelor. Thrombosis J. 2024; 22:8. doi:10.1186/s12959-023-00559-3.
7. Rauf MA, Ziyad M, Mahmood N, Ullah R, Ahmad F, Ullah I, et al. Evaluating the safety and efficacy of ticagrelor vs. clopidogrel following percutaneous coronary intervention in chronic coronary disease. Cureus. 2025; 17(1):e77610. doi:10.7759/cureus.77610.
8. Moak JH, Muck AE, Brady WJ. ST-segment elevation myocardial infarction mimics: The differential diagnosis of non-acute coronary syndrome causes of ST-segment/T-wave abnormalities in the chest pain patient. Turk J Emerg Med. 2024; 24(4):206-17. doi:10.4103/tjem.tjem_137_24.
9. Lattuca B, Mazeau C, Cayla G, Ducrocq G, Guedeney P, Laredo M, et al. Ticagrelor vs clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome. JACC Cardiovasc Interv. 2024; 17(3):359-70. doi:10.1016/j.jcin.2023. 12.011.
10. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021; 21(1):241. doi:10.1186/s12874-021-01440-5.
11. Klein LW. Ticagrelor versus clopidogrel for acute coronary syndrome: have things changed? Am J Cardiol. 2024; 210:315-6. doi:10.1016/j.amjcard.2023.10.078.
12. Xi Z, Li J, Qiu H, Guo T, Wang Y, Li Y, et al. Ticagrelor vs. clopidogrel after complex percutaneous coronary intervention in patients with stable coronary artery disease. Front Cardiovasc Med. 2021; 8:768190. doi:10.3389/fcvm.2021.768190.
13. Hakeem A, Shah JA, Kumar R, Ali A, Lakho AA, Zeeshan H, et al. Twice-daily clopidogrel vs ticagrelor to reduce short-term major adverse cardiovascular events after primary percutaneous coronary intervention: the TADCLOT trial. J Am Coll Cardiol. 2025:S0735-1097(25)07549-7. doi:10.1016/j.jacc.2025.08.041.
14. Hamilos M, Kanakakis J, Anastasiou I, Karvounis C, Vasilikos V, Goudevenos J, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial. EuroIntervention. 2021; 16(14):1163-9. doi:10.4244/EIJ-D-20-00268.
15. Zheng MY, Zhang YK, Hu ST, Gu TS, Jiang C, Zhang JK, Ticagrelor vs. clopidogrel in ST elevation myocardial infarction patients with hemoglobin >160. Eur Heart J. 2024; 45(1):1677. doi:10.1093/eurheartj/ehae666.1677.
16. Yan Y, Xu H, Zhao Y, Lin S, Zheng Y. Ticagrelor versus clopidogrel in patients with left main coronary artery stenting. Cardiovasc Drugs Ther. 2024. doi:10.1007/s10557-024-07636-3.
17. Qiu M, Zhi X, Liu H, Liang Z, Wang B, Xu K, et al. Impact of ticagrelor vs. clopidogrel in patients with acute coronary syndrome undergoing left main percutaneous coronary intervention. Cardiology Discovery. 2025; 5(1):39-46. doi:10.1097/CD9.0000000000000134.
18. Bari AM, Raza M, Ijaz ul Haq, Saleem Q, Sofia, Anika. Outcome of ticagrelor versus clopidogrel in ACS patients undergoing PCI. IJBR. 2024; 2(2): 594-9. doi:10.70749/ijbr.v2i02.251.
19. Zhou C, Zhang M, Zhao Z, Li E, Zhao Y, Luo W, et al. Clopidogrel vs. ticagrelor in ST-elevation myocardial infarction complicated by cardiogenic shock undergoing primary PCI : findings from a national, multicenter registry. Thromb J. 2025; 23(1):38. doi:10.1186/s12959-025-00721-z.
20. Koshy AN, Giustino G, Sartori S, Hooda A, Feng Y, Snyder C, et al. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention. 2023; 18(15):1244-53. doi:10.4244/EIJ-D-22-00654.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Sharif Medical & Dental College is licensed and distributed under the terms of Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
